MolNFT v1 · #169839 · protein
DCN1 bound to di-1859
6XOO · Lysozyme, DCN1-like protein 1 chimera: “DCN1 bound to di-1859”. X-ray diffraction, 1 ligand (H8S), 4 pockets (best druggability 0.68). MolNFT v1 #169839 on GenesisL1: 3D structure, binding sites and pockets in GL1X.
- PDB
- 6XOO
- Type
- protein
- Length
- 356 residues
- Chains
- 1
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- Lysozyme, DCN1-like protein 1 chimera
- EC
- 3.2.1.17
- UniProt
- D9IEF7, Q96GG9
- Ligands
- H8S
- Pockets
- 4 · best druggability 0.68
Structure
x-ray diffraction · 1 distinct chain · 63% helix, 7% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| A | Lysozyme, DCN1-like protein 1 chimera (EC 3.2.1.17) | protein | 356 | 63% helix, 7% strand | D9IEF7, Q96GG9 |
Ligands and binding sites
- H8S · N-{(1S)-1-cyclohexyl-2-[(2-methylpropanoyl) amino]ethyl}-N~2~-propanoyl-3-[6-(propan-2-yl)-1,3-benzothiazol-2-yl]-L-alaninamide · ligand · chains A
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Pockets
4 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 169 | 0.68 | 0.87 | 25 | H8S |
| 2 | 348 | 0.58 | 0.76 | 40 | empty |
| 3 | 113 | 0.45 | 0.78 | 20 | empty |
| 4 | 72 | 0.32 | 0.75 | 16 | empty |
Modifications
Observed in the structure: 1 covalent (covalent ligand).
Compared structures
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt D9IEF7
- Every structure of UniProt Q96GG9
- Elsewhere: RCSB PDB 6XOO · PDBe 6XOO · UniProt D9IEF7 · UniProt Q96GG9
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.